(Q52966694)

10 May 2018

meta-analysis

0 references

title

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. (English)

1 reference

10 May 2018

1 reference

lymphoblastic leukemia

1 reference

Gaynon PS

1

1 reference

10 May 2018

Trigg ME

2

1 reference

10 May 2018

Heerema NA

3

1 reference

10 May 2018

Sensel MG

4

1 reference

10 May 2018

Sather HN

5

1 reference

10 May 2018

Hammond GD

6

1 reference

10 May 2018

Bleyer WA

7

1 reference

10 May 2018

publication date

1 December 2000

1 reference

10 May 2018

published in

Leukemia

1 reference

10 May 2018

volume

14

1 reference

10 May 2018

issue

12

1 reference

10 May 2018

page(s)

2223-2233

1 reference

10 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2401939

exact match

0 references

cites work

Prevention of central nervous system leukemia by irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Evaluation of radiation therapy factors in prophylactic central nervous system irradiation for childhood leukemia: a report from the Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: comparison of 1800 rad and 2400 rad. A report for Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

[The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukaemia (ALL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report fr

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Second neoplasms after acute lymphoblastic leukemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Expression profiling in cancer using cDNA microarrays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Assessing whether to perform a confirmatory randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

1 reference

7 January 2021

Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401939

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2401939

1 reference

10 May 2018

Dimensions Publication ID

1032093990

0 references

1 reference

10 May 2018